Evidence for a role of phospholipid oxidation products in atherogenesis

Trends Cardiovasc Med. 2001 Apr-May;11(3-4):142-7. doi: 10.1016/s1050-1738(01)00098-6.

Abstract

There is growing evidence for the accumulation of phospholipid oxidation products (some of which can also be formed enzymatically) in several chronic disease processes including atherosclerosis. There also is considerable evidence that enzymes involved in hydrolysis of these phospholipids (present in both lipoproteins and cells) may be important in regulation of atherogenesis. In vitro studies suggest that these lipids can activate vascular wall cells to states that contribute to the atherosclerotic process. This review focuses on two types of bioactive phospholipids: phosphatidyl cholines in which the sn-2 fatty acid has been modified by oxidation and lysophosphatidic acid in which both the sn-2 and sn-3 positions have been modified. The mechanism by which these phospholipid oxidation products activate cells has revealed the presence of several different receptors and signal transduction pathways.

Publication types

  • Review

MeSH terms

  • Animals
  • Arteriosclerosis / etiology*
  • Arteriosclerosis / metabolism*
  • Humans
  • Molecular Structure
  • Oxidation-Reduction
  • Phospholipids / physiology*

Substances

  • Phospholipids